Calidi Biotherapeutics, Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing that it entered into a stock purchase agreement on September 17, 2026, and closed a registered direct offering of common stock on September 21, 2026.
Key Highlights
- Shares sold: An aggregate of 1,025,640 shares of common stock, par value $0.0001 per share, were issued and sold directly to accredited investors and/or qualified institutional buyers.
- Purchase price: Shares were sold at $1.17 per share.
- Gross proceeds: Approximately $1.2 million, before deducting estimated offering expenses payable by the company.
- No placement agent: The company did not engage an underwriter, placement agent, broker-dealer, or other agent, and no commissions or fees were paid in connection with the sale.
- Lock-up period: Directors and executive officers agreed not to transfer or dispose of common stock or related securities for 60 days following the closing.
- Intended use of proceeds: The company disclosed it intends to use net proceeds for working capital and general corporate purposes.
Calidi Biotherapeutics Completes Direct Share Sale Without Placement Agent
According to the filing, Calidi Biotherapeutics, Inc. (NYSE American:CLDI) entered into a stock purchase agreement on September 17, 2026, with certain accredited investors and/or qualified institutional buyers. Under the agreement, the company agreed to issue and sell 1,025,640 shares of its common stock at a purchase price of $1.17 per share in a registered direct offering. The offering closed on September 21, 2026, generating gross proceeds of approximately $1.2 million before estimated offering expenses.
The filing states that the shares were offered and sold pursuant to the company's effective shelf registration statement on Form S-3 (File No. 333-282456), which was declared effective by the SEC on October 10, 2024, along with the base prospectus and a prospectus supplement dated September 17, 2026. The company reported that it did not engage any underwriter, placement agent, or broker-dealer, and no underwriting discounts, commissions, or similar fees were paid in connection with the transaction.
The purchase agreement includes a 45-day restriction, subject to certain exceptions, during which the company agreed it will not issue, offer, sell, or otherwise dispose of any equity securities or equity-linked securities without the prior written consent of purchasers holding more than 50% in interest of the shares purchased. Additionally, the company's directors and executive officers entered into lock-up agreements restricting transfers or dispositions of common stock or convertible securities for 60 days following the closing. The company's chief financial officer, Andrew Jackson, signed the filing on September 22, 2026.
What Was Disclosed
Calidi Biotherapeutics disclosed the terms of a completed registered direct offering of 1,025,640 shares at $1.17 per share, raising approximately $1.2 million in gross proceeds, along with related lock-up and equity issuance restrictions on the company and its insiders.



Please wait processing your request...